ProCE Banner Activity

BICSTaR: BIC/FTC/TAF Effectiveness and Safety by Demographics and Baseline Characteristics at 24 Mo

Slideset Download
Conference Coverage

Investigators state that data support effectiveness, safety, and persistence of BIC/FTC/TAF in treatment-naive and treatment-experienced PWH with a high prevalence of comorbidities at baseline.

Released: November 07, 2022


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare